ImageneBio, Inc. — Director's Dealing 2022

Jan 13, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2022-01-10

Reporting Person: Zhang Xiaoyan Michelle (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-10	Common Stock	M	36	$2.1462	Acquired	44511	Direct
2022-01-10	Common Stock	S	36	$12.00	Disposed	44475	Direct
2022-01-11	Common Stock	M	964	$2.1462	Acquired	45439	Direct
2022-01-11	Common Stock	S	964	$12.00	Disposed	44475	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-10	Stock Option (Right to Buy)	$2.1462	M	36	Disposed	2028-12-17	Common Stock (36)	Direct
2022-01-11	Stock Option (Right to Buy)	$2.1462	M	964	Disposed	2028-12-17	Common Stock (964)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2021.

F2: 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.